ABBV-438 is an antibody-drug conjugate targeting CD38, a glycoprotein expressed on tumor cells and immune cells. The antibody binds CD38 on tumor cells, leading to cell death through an undisclosed cytotoxic mechanism. It is being studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.